Greg M. Thurber

Dr. Greg M. Thurber

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2008 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
GTGreg M. Thurber
Greg M. Thurber
MSMichael M. Schmidt
Michael M. Schmidt
KWK. Dane Wittrup
K. Dane Wittrup

12 January 2009 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
NDNeal K. Devaraj
Neal K. Devaraj
EKEdmund J. Keliher
Edmund J. Keliher
GTGreg M. Thurber
Greg M. Thurber
MNMatthias Nahrendorf
Matthias Nahrendorf
RWRalph Weissleder
Ralph Weissleder

19 February 2013 in Nature Communications
Verified
Journal Article
Closed access
PDF file
GTGreg M. Thurber
Greg M. Thurber
KYKaty S. Yang
Katy S. Yang
TRThomas Reiner
Thomas Reiner
RKRainer H. Kohler
Rainer H. Kohler
PSPeter Sorger
Peter Sorger
RWRalph Weissleder
Ralph Weissleder

12 March 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
NDNeal K. Devaraj
Neal K. Devaraj
GTGreg M. Thurber
Greg M. Thurber
EKEdmund J. Keliher
Edmund J. Keliher
BMBrett Marinelli
Brett Marinelli
RWRalph Weissleder
Ralph Weissleder
There has been intense interest in the development of selective bioorthogonal reactions or “click” chemistry that can proceed in live animals. Until now however, most reactions still require vast surpluses of reactants because of steep temporal and spatial concentration gradients. Using computational modeling and design of pharmacokinetically optimized reactants, we have developed a predictable method for efficient in vivo click reactions. Specifically, we show that polymer modified tetrazines (PMT) are a key enabler for in vivo bioorthogonal chemistry based on the very fast and catalyst-free [4 + 2] tetrazine/ trans -cyclooctene cycloaddition. Using fluorescent PMT for cellular resolution and 18 F labeled PMT for whole animal imaging, we show that cancer cell epitopes can be easily reacted in vivo. This generic strategy should help guide the design of future chemistries and find widespread use for different in vivo bioorthogonal applications, particularly in the biomedical sciences.

7 January 2008 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
GTGreg M. Thurber
Greg M. Thurber
MSM Schmidt
M Schmidt
KWK Wittrup
K Wittrup

1 January 2012
Verified
Book Chapter
Open access
KWK. Dane Wittrup
K. Dane Wittrup
GTGreg M. Thurber
Greg M. Thurber
MSMichael M. Schmidt
Michael M. Schmidt
JRJohn J. Rhoden
John J. Rhoden
Theoretical analyses of targeting agent pharmacokinetics provides specific guidance with respect to desirable design objectives such as agent size, affinity, and target antigen. These analyses suggest that IgG-sized macromolecular constructs exhibit the most favorable balance between systemic clearance and vascular extravasation, resulting in maximal tumor uptake. Quantitative predictions of the effects of dose and binding affinity on tumor uptake and penetration are also provided. The single bolus dose required for saturation of xenografted tumors in mice can be predicted from knowledge of antigen expression level and metabolic half-life. The role of high binding affinity in tumor uptake can be summarized as: essential for small peptides, less important for antibodies, and negligible for nanoparticles.